These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6985642)

  • 1. Effector mechanisms of cytolytically activated macrophages. II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases.
    Adams DO; Kao KJ; Farb R; Pizzo SV
    J Immunol; 1980 Jan; 124(1):293-300. PubMed ID: 6985642
    [No Abstract]   [Full Text] [Related]  

  • 2. Effector mechanisms of cytolytically activated macrophages. I. Secretion of neutral proteases and effect of protease inhibitors.
    Adams DO
    J Immunol; 1980 Jan; 124(1):286-92. PubMed ID: 6985641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a multistep mechanism of cytolysis by BCG-activated macrophages: the interrelationship between the capacity for cytolysis, target binding, and secretion of cytolytic factor.
    Adams DO; Marino PA
    J Immunol; 1981 Mar; 126(3):981-7. PubMed ID: 7007505
    [No Abstract]   [Full Text] [Related]  

  • 4. The binding of BCG-activated macrophages to tumor targets stimulates secretion of cytolytic factor.
    Johnson WJ; Whisnant CC; Adams DO
    J Immunol; 1981 Nov; 127(5):1787-92. PubMed ID: 6795261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The production of fibrinolysis inhibitors as a parameter of the activation state in murine macrophages.
    Klimetzek V; Sorg C
    Eur J Immunol; 1979 Aug; 9(8):613-9. PubMed ID: 499330
    [No Abstract]   [Full Text] [Related]  

  • 6. BCG-activated macrophages: comparison as effectors in direct tumor-cell cytotoxicity and antibody dependent cell-mediated cytotoxicity.
    Adams DO; Koren HS
    Adv Exp Med Biol; 1979; 121B():195-201. PubMed ID: 397747
    [No Abstract]   [Full Text] [Related]  

  • 7. Studies on the antibody-dependent cell-mediated cytotoxicity (ADCC) of thioglycollate-stimulated and BCG-activated peritoneal macrophages.
    Koren HS; Anderson SJ; Adams DO
    Cell Immunol; 1981 Jan; 57(1):51-61. PubMed ID: 7011574
    [No Abstract]   [Full Text] [Related]  

  • 8. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guérin involves class II transactivator and depends on the Nramp1 gene.
    Wojciechowski W; DeSanctis J; Skamene E; Radzioch D
    J Immunol; 1999 Sep; 163(5):2688-96. PubMed ID: 10453010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic analysis of macrophages: a potential way to identify novel proteins associated with activation of macrophages for tumor cell killing.
    Zhang L; Zhu H; Lun Y; Yan D; Yu L; Du B; Zhu X
    Cell Mol Immunol; 2007 Oct; 4(5):359-67. PubMed ID: 17976316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ADCC capacity of macrophages from C3H/HeJ and A/J mice can be augmented by BCG.
    Koren HS; Meltzer MS; Adams DO
    J Immunol; 1981 Mar; 126(3):1013-5. PubMed ID: 7007498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective tumoricidal capacity of macrophages from P/J mice: characterization of the macrophage cytotoxic defect after in vivo and in vitro activation stimuli.
    Boraschi D; Meltzer MS
    J Immunol; 1980 Aug; 125(2):771-6. PubMed ID: 6993562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective tumoricidal capacity of macrophages from P/J mice: tumoricidal defect involves abnormalities in lymphokine-derived activation stimuli and in mononuclear phagocyte responsiveness.
    Boraschi D; Meltzer MS
    J Immunol; 1980 Aug; 125(2):777-82. PubMed ID: 6993563
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunoregulation of antitumor response; differential secretion of arachidonic acid metabolites by macrophages during stimulation in vitro with BCG and Corynebacterium parvum.
    Tomecki J; Sukiennik J; Kordowiak A
    Arch Immunol Ther Exp (Warsz); 1993; 41(1):45-50. PubMed ID: 8239907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of Bacillus Calmette--Guérin-activated macrophages and neoplastic cells in vitro II. The relationship of selective binding to cytolysis.
    Marino PA; Adams DO
    Cell Immunol; 1980 Aug; 54(1):26-35. PubMed ID: 6773673
    [No Abstract]   [Full Text] [Related]  

  • 15. Macrophages in resistance to rickettsial infections: characterization of lymphokines that induce rickettsiacidal activity in macrophages.
    Nacy CA; Leonard EJ; Meltzer MS
    J Immunol; 1981 Jan; 126(1):204-7. PubMed ID: 7005333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.
    Tsung K; Dolan JP; Tsung YL; Norton JA
    Cancer Res; 2002 Sep; 62(17):5069-75. PubMed ID: 12208763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Level of activation determines whether inflammatory peritoneal and intratumoral macrophages will promote or suppress in vitro development of cytolytic T lymphocyte activity.
    Gillespie GY; Russell SW
    J Reticuloendothel Soc; 1980 May; 27(5):535-45. PubMed ID: 7373614
    [No Abstract]   [Full Text] [Related]  

  • 18. Macrophage neutral proteinases and defense of the lung.
    Gordon S
    Fed Proc; 1977 Dec; 36(13):2707-11. PubMed ID: 200492
    [No Abstract]   [Full Text] [Related]  

  • 19. Macrophage-induced enhancement of endogenous tumor lysosome activity.
    Urban JL
    Cancer Res; 1981 Jun; 41(6):2221-9. PubMed ID: 7237422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced in vitro macrophage cytotoxicity against interferon-treated B16 melanoma cells.
    Fleischmann CM; Fleischmann WR
    J Biol Regul Homeost Agents; 1995; 9(4):139-45. PubMed ID: 8844338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.